{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:03:36Z","timestamp":1761843816209},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ccl.2008.06.007","type":"journal-article","created":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T09:27:07Z","timestamp":1224149227000},"page":"547-560","source":"Crossref","is-referenced-by-count":23,"title":["Extended-Release Niacin\/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors"],"prefix":"10.1016","volume":"26","author":[{"given":"John F.","family":"Paolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darbie","family":"Maccubbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine M.","family":"Norquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Gerard","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"McCrary Sisk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yale B.","family":"Mitchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ccl.2008.06.007_bib1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)","volume":"285","author":"Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ccl.2008.06.007_bib2","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2008.06.007_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jama.284.3.311","article-title":"Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality, and to longevity","volume":"284","author":"Stamler","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ccl.2008.06.007_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000120621.99766.ef","article-title":"European guidelines on cardiovascular disease prevention in clinical practice","volume":"10","author":"DeBacker","year":"2003","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.ccl.2008.06.007_bib5","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1067\/mhj.2002.130301","article-title":"High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease","volume":"144","author":"Gotto","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccl.2008.06.007_bib6","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/hc4401.098467","article-title":"Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins\u2014an idea whose time for testing is coming, part I","volume":"104","author":"Shah","year":"2001","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ccl.2008.06.007_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2008.06.007_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.54.101601.152409","article-title":"Atheroprotective effects of high-density lipoproteins","volume":"54","author":"Assmann","year":"2003","journal-title":"Annu Rev Med"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2008.06.007_bib9","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0021-9150(98)00219-6","article-title":"Triglycerides are more important in atherosclerosis than epidemiology has suggested","volume":"141","author":"Durrington","year":"1998","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ccl.2008.06.007_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"issue":"4a","key":"10.1016\/j.ccl.2008.06.007_bib11","doi-asserted-by":"crossref","first-page":"7b","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J\u00a0Cardiol"},{"issue":"Suppl M","key":"10.1016\/j.ccl.2008.06.007_bib12","first-page":"8","article-title":"The emergence of triglycerides as a significant independent risk factor in coronary artery disease","volume":"19","author":"Assmann","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2008.06.007_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"ADA\/ACC consensus statement","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ccl.2008.06.007_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.tips.2006.05.008","article-title":"The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target","volume":"27","author":"Offermanns","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ccl.2008.06.007_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem"},{"key":"10.1016\/j.ccl.2008.06.007_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.ccl.2008.06.007_bib17","series-title":"The pharmacological basis of therapeutics","first-page":"971","article-title":"Drug therapy for hypercholesterolemia and dyslipidemia","author":"Mahley","year":"2001"},{"key":"10.1016\/j.ccl.2008.06.007_bib18","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"National Cholesterol Education Program (NCEP) Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","author":"National Institutes of Health","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2008.06.007_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11883-000-0093-1","article-title":"Mechanism of action of niacin on lipoprotein metabolism","volume":"2","author":"Kamanna","year":"2000","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"10.1016\/j.ccl.2008.06.007_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"The Coronary Drug Project Research Group","year":"1975","journal-title":"J Am Med Assoc"},{"issue":"22","key":"10.1016\/j.ccl.2008.06.007_bib21","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatinstatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.ccl.2008.06.007_bib22","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccl.2008.06.007_bib23","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen-year mortality in coronary drug project patients long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2008.06.007_bib24","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol\u2013niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"J Am Med Assoc"},{"issue":"19","key":"10.1016\/j.ccl.2008.06.007_bib25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2008.06.007_bib26","first-page":"229","article-title":"Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice","volume":"62","author":"Birjmohun","year":"2004","journal-title":"Neth J Med"},{"key":"10.1016\/j.ccl.2008.06.007_bib27","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A new extended-release niacin (NIASPAN): efficacy, tolerability, and safety in hypercholesterolemic patients","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol"},{"issue":"6A","key":"10.1016\/j.ccl.2008.06.007_bib28","first-page":"32C","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccl.2008.06.007_bib29","author":"Abbott Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.ccl.2008.06.007_bib30","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.ccl.2008.06.007_bib31","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1185\/03007990802083408","article-title":"Dosage, titration, and gaps in treatment with extended- release niacin in clinical practice","volume":"24","author":"Kamal-Bahl","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ccl.2008.06.007_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.amjcard.2006.08.063","article-title":"Discontinuation of lipid-modifying drugs among commercially insured United States patients in recent clinical practice","volume":"99","author":"Kamal-Bahl","year":"2007","journal-title":"Am J Cardiol"},{"issue":"9 Suppl A","key":"10.1016\/j.ccl.2008.06.007_bib33","first-page":"273A","article-title":"Flushing experience and discontinuation with niacin in clinical practice","volume":"49","author":"Kamal-Bahl","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2008.06.007_bib34","first-page":"A255","article-title":"The impact of niacin-induced flushing during the first week of therapy in a real-world setting","volume":"51","author":"Trovato","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2008.06.007_bib35","series-title":"The pharmacological basis of therapeutics","first-page":"669","article-title":"Lipid-derived autacoids, eicosanoids, and platelet-activating factor","author":"Morrow","year":"2001"},{"key":"10.1016\/j.ccl.2008.06.007_bib36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1525-1497.1997.07118.x","article-title":"Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions","volume":"12","author":"Jungnickel","year":"1997","journal-title":"J Gen Intern Med"},{"issue":"2","key":"10.1016\/j.ccl.2008.06.007_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"issue":"4","key":"10.1016\/j.ccl.2008.06.007_bib38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/clpt.1982.63","article-title":"Aspirin blocks nicotinic acid-induced flushing","volume":"31","author":"Wilkin","year":"1982","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ccl.2008.06.007_bib39","first-page":"165","article-title":"The effect of aspirin on niacin-induced cutaneous reactions","volume":"34","author":"Whelan","year":"1992","journal-title":"J\u00a0Fam Pract"},{"key":"10.1016\/j.ccl.2008.06.007_bib40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1600-0773.1977.tb02678.x","article-title":"Influence of indomethacin on flush induced by nicotinic acid in man","volume":"41","author":"Svedmyr","year":"1977","journal-title":"Acta Pharmacol Toxicol"},{"key":"10.1016\/j.ccl.2008.06.007_bib41","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(81)92627-1","article-title":"Is cutaneous flushing prostaglandin-mediated?","volume":"1","author":"Phillips","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.06.007_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/clpt.1985.170","article-title":"Prostaglandins and nicotinate-provoked increase in cutaneous blood flow","volume":"38","author":"Wilkin","year":"1985","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.ccl.2008.06.007_bib43","first-page":"643","article-title":"Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing","volume":"25","author":"Nozaki","year":"1987","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"6","key":"10.1016\/j.ccl.2008.06.007_bib44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0090-6980(79)90055-8","article-title":"Prostaglandins contribute to the vasodilation induced by nicotinic acid","volume":"17","author":"Eklund","year":"1979","journal-title":"Prostaglandins"},{"key":"10.1016\/j.ccl.2008.06.007_bib45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0090-6980(84)90033-9","article-title":"Effects of intravenous infusions of prostaglandin D2 in man","volume":"28","author":"Heavy","year":"1984","journal-title":"Prostaglandins"},{"issue":"17","key":"10.1016\/j.ccl.2008.06.007_bib46","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ccl.2008.06.007_bib47","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ccl.2008.06.007_bib48","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1185\/030079907X199637","article-title":"Validation of a questionnaire to assess niacin-induced cutaneous flushing","volume":"23","author":"Norquist","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.ccl.2008.06.007_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan disability scale","volume":"23","author":"Sheehan","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.ccl.2008.06.007_bib50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccl.2008.06.007_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidemia","author":"Maccubbin","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ccl.2008.06.007_bib52","first-page":"II 127","article-title":"Lipid-altering efficacy and safety profile of coadministered extended-release niacin\/laropiprant and simvastatin in patients with dyslipidemia","volume":"116","author":"Gleim","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2008.06.007_bib53","unstructured":"Merck & Co., Inc., Study memo; data on file."}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865108000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865108000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T18:17:32Z","timestamp":1557857852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865108000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0733865108000702"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2008.06.007","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}